UK – Venetoclax gets NICE approval for chronic lymphocytic leukaemia

The National Institute for Health and Care Excellence (NICE) has recommended AbbVie’s Venclyxto (venetoclax) to benefit thousands of adults with chronic lymphocytic leukaemia (CLL).

The new treatment Venclyxto has been recommended with Rituxan (rituximab) for adults with relapsed or refractory chronic lymphocytic leukaemia.

Venclyxto is a first-in-class, oral, once-daily medicine that selectively inhibits the function of the BCL-2 protein, restoring the body’s ability to trigger cancer cell self-destruction.

Currently the most common first line treatment for CLL is chemotherapy, with limited options after relapse.

Meindert Boysen, director of NICE’s Centre for Health Technology Evaluation, said: “We are very pleased to announce another treatment option for people with relapsed or refractory chronic lymphocytic leukaemia will be available on the NHS…